FIRST AMENDMENT TO PLASMA PURCHASE AGREEMENTPlasma Purchase Agreement • June 22nd, 2012 • Adma Biologics, Inc. • Blank checks • Delaware
This First Amendment to the Plasma Purchase Agreement (this “Amendment #1”) by and between Biotest Pharmaceuticals Corporation, a Delaware corporation, having a place of business at 5800 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487 (“BPC”) and ADMA Biologics, Inc., a Delaware corporation, having a place of business at 65 Commerce Way, Hackensack, New Jersey 07601 (“ADMA”) is effective as of December 1, 2011 (“Effective Date”),
PLASMA PURCHASE AGREEMENTPlasma Purchase Agreement • November 14th, 2006 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • Florida
THIS PLASMA PURCHASE AGREEMENT (“Agreement”) is made and entered into as of this 03 day of December, 2003, by and between Bayer HealthCare LLC, a Delaware limited liability company, with its principal place of business in Tarrytown, New York and an address at 79 T.W. Alexander Dr., 4101 Research Commons, Research Triangle Park, North Carolina 27610 (“Bayer”), and Nabi Biopharmaceuticals (formerly Nabi) a Delaware, corporation, with its principal place of business at 5800 Park of Commerce Blvd NW, Boca Raton, FL, 33487 (“Nabi”).
THIRD AMENDMENT TO PLASMA PURCHASE AGREEMENTPlasma Purchase Agreement • May 13th, 2016 • Adma Biologics, Inc. • Biological products, (no disgnostic substances)
This Third Amendment to the Plasma Purchase Agreement (this “Amendment #3”) by and between Biotest Pharmaceuticals Corporation, a Delaware corporation, having a place of business at 5800 Park of Commerce Boulevard NW, Boca Raton, Florida 33487 (“BPC”) and ADMA Biologics, Inc., a Delaware corporation, having a place of business at 465 Route 17 South, Ramsey, New Jersey 07446 (“ADMA”) is effective as of May 23, 2016 (“Effective Date”).
PLASMA PURCHASE AGREEMENTPlasma Purchase Agreement • August 11th, 2017 • Adma Biologics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS PLASMA PURCHASE AGREEMENT (“Agreement”) between Biotest Pharmaceuticals Corporation, a Delaware corporation, having a place of business at 5800 Park of Commerce Boulevard, NW, Boca Raton, Florida 33487 (“BPC”) and ADMA BioManufacturing, LLC., a Delaware limited liability corporation, having a place of business at 465 Route 17 South, Ramsey New Jersey 07446 (“ADMA”) shall be effective as of June 6, 2017 (the “Effective Date”). BPC and ADMA are each sometimes referred to herein individually as a “Party” or collectively as the “Parties”.
ContractPlasma Purchase Agreement • August 4th, 2020 • Liminal BioSciences Inc. • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE LIMINAL BIOSCIENCES INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIMINAL BIOSCIENCES INC. IF PUBLICLY DISCLOSED.
SECOND AMENDMENT TO PLASMA PURCHASE AGREEMENT NORMAL SOURCE PLASMA PURCHASE FROM BPC TO ADMAPlasma Purchase Agreement • May 12th, 2021 • Adma Biologics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment to the Plasma Purchase Agreement (this “Amendment #2”) by and between Grifols Worldwide Operations Limited, a corporation having a place of business at Grange Castle Business Park, Grange Castle, Clondalkin, Dublin 22, Ireland (“GWWO”), as the successor-in-interest to BPC Plasma, Inc., formerly, Biotest Pharmaceuticals Corporation (“BPC”), and ADMA BioManufacturing, LLC., a Delaware limited liability corporation having a place of business at 465 Route 17 South, Ramsey, New Jersey 07446 (“ADMA”), is effective as of May 12, 2021 execution (the “Effective Date”).
ContractPlasma Purchase Agreement • March 23rd, 2016 • Adma Biologics, Inc. • Biological products, (no disgnostic substances)
PLASMA PURCHASE AGREEMENTPlasma Purchase Agreement • August 4th, 2020 • Liminal BioSciences Inc. • Pharmaceutical preparations
This Plasma Purchase Agreement (the “Agreement”) is made, entered into and effective as of the 26th day of June 2017 (the “Effective Date”) by and between Prometic Plasma Resources Inc., a corporation existing under the law of Canada, having its registered office located at 440, Boulevard Armand-Frappier, Suite 300, Laval, Québec H7V 4B4 Canada (“Prometic”), and Biotest Pharmaceuticals Corporation, a Delaware corporation, having an address at 5800 Park of Commerce Boulevard NW, Boca Raton, Florida 33487 USA (“BPC”). Prometic and BPC are at times referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
PLASMA PURCHASE AGREEMENT AMENDMENTPlasma Purchase Agreement • November 14th, 2006 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances)
This Plasma Purchase Agreement Amendment (“Amendment”) is entered into and effective as of September 13, 2006 (“Amendment Effective Date”) by and between Nabi Biopharmaceuticals (“Nabi”), a Delaware corporation having an address at 5800 Park of Commerce Blvd., N.W., Boca Raton, Florida 33487, and Talecris Biotherapeutics, Inc., a Delaware corporation having an address at 79 T.W. Alexander Drive, 4101 Research Commons, Research Triangle Park, North Carolina 27709 (“Talecris”), each of which is at times referred to herein individually as “Party” and collectively as “Parties.” The Amendment is intended to supplement and alter the Plasma Purchase Agreement entered into on December 3, 2003 by Nabi and Bayer HealthCare LLC (“Agreement”). The Agreement, except as amended hereby, remains in full force and effect.
ContractPlasma Purchase Agreement • August 4th, 2020 • Liminal BioSciences Inc. • Pharmaceutical preparations • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE LIMINAL BIOSCIENCES INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIMINAL BIOSCIENCES INC. IF PUBLICLY DISCLOSED.
ContractPlasma Purchase Agreement • August 4th, 2020 • Liminal BioSciences Inc. • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE LIMINAL BIOSCIENCES INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO LIMINAL BIOSCIENCES INC. IF PUBLICLY DISCLOSED.
FOURTH AMENDMENT TO PLASMA PURCHASE AGREEMENTPlasma Purchase Agreement • August 11th, 2017 • Adma Biologics, Inc. • Biological products, (no disgnostic substances)
This Fourth Amendment to the Plasma Purchase Agreement (this “Amendment #4”) by and between Biotest Pharmaceuticals Corporation, a Delaware corporation having a place of business at 5800 Park of Commerce Boulevard, NW, Boca Raton, Florida 33487(“BPC”) and ADMA Biologics, Inc., a Delaware corporation having a place of business at 465 Route 17 South, Ramsey, New Jersey 07446 (“ADMA”) is effective as of June 6, 2017 (the “ Effective Date”).
November , 2006Plasma Purchase Agreement • September 24th, 2007 • Talecris Biotherapeutics Holdings Corp. • Pharmaceutical preparations • New York
PLASMA PURCHASE AGREEMENTPlasma Purchase Agreement • August 4th, 2020 • Liminal BioSciences Inc. • Pharmaceutical preparations
This Plasma Purchase Agreement (the “Agreement”) is made, entered into and effective as of the 6th day of November, 2015 (the “Effective Date”) by and between ProMetic Plasma Resources Inc., a corporation existing under the law of Canada, having its registered office located at 440, Boulevard Armand-Frappier, Suite 300, Laval, Québec H7V 4B4 (“ProMetic”), and Interstate Blood Bank, Inc., a Tennessee corporation (“IBBI”), having an address at 5700 Pleasant View Road, Memphis, Tennessee 38134. ProMetic and IBBI are at times referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
